Theravance posted $3.6 million in net income for Q3 2025, reversing a prior-year loss, as YUPELRI net sales hit a record and the company reached non-GAAP breakeven. Cash position remained strong at $333 million.

Theravance posted solid Q2 2025 results, achieving profitability due to a $7.5M milestone payment for YUPELRI’s China approval and continued revenue growth from its U.S. partnership with Viatris. The sale of its TRELEGY royalty interest also boosted results with a $75.1M gain.

Theravance Biopharma reported a total revenue of $15.4 million for Q1 2025, primarily from Viatris collaboration revenue. The company saw solid growth in YUPELRI net sales and continued progress in the CYPRESS study for ampreloxetine, with enrollment nearing completion.

Theravance Biopharma concluded 2024 with record fourth quarter YUPELRI net sales and profitability, achieving a $50 million TRELEGY related sales milestone. The company also made steady progress in its CYPRESS study and ended the quarter with $88 million in cash.

Theravance Biopharma reported financial and operational results for the third quarter of 2024, highlighting strong YUPELRI demand and progress on the CYPRESS study. The company also announced the formation of a Strategic Review Committee to assess alternatives to unlock shareholder value.

Theravance Biopharma's YUPELRI net sales decreased 1% from the prior quarter. The company is exploring opportunities to unlock value from its Irish tax assets. Patent litigation is pending against four companies.

Theravance Biopharma reported its first quarter 2024 financial results, highlighting a solid performance in YUPELRI hospital sales and ongoing progress with the CYPRESS study for ampreloxetine.

Theravance Biopharma reported strong performance in 2023, achieving financial objectives in the fourth quarter and exceeding the annual goal for YUPELRI hospital growth. The company looks forward to continuing YUPELRI net sales growth in 2024 and completing enrollment in the CYPRESS study in the second half of the year.

Theravance Biopharma announced its Q3 2023 financial results, highlighting YUPELRI growth and expense management leading to a non-GAAP loss of less than $1 million. The company is progressing with the Phase 3 CYPRESS study for ampreloxetine.

Theravance Biopharma reported a $2.7 million increase in total revenue for the second quarter compared to the same period in 2022, primarily driven by an increase in YUPELRI net sales. The company completed $80.5 million of share buybacks in Q2 2023 and remains on track to achieve non-GAAP profitability in H2 2023, subject to YUPELRI’s increased net sales growth.

Theravance Biopharma reported first quarter 2023 financial results, highlighting a focus on commercial and development efforts. YUPELRI retail new patient starts grew by 61% and the company initiated enrollment for the CYPRESS Phase 3 study for ampreloxetine.

Theravance Biopharma announced its Q4 and full year 2022 financial results, along with strategic actions to sharpen focus and enhance shareholder value. The company is focused on driving YUPELRI’s growth, advancing the ampreloxetine pipeline, upsizing the capital return program to $325 million, and achieving non-GAAP profitability by the second half of the year.

Theravance Biopharma reported its Q3 2022 financial results, highlighting the completion of the sale of its TRELEGY royalty interest to Royalty Pharma for over $1.5 billion in potential total value. The company is now debt-free and focused on value creation.

Theravance Biopharma reported its Q2 2022 financial results, highlighting YUPELRI's strongest quarter of sales to date and a potential NDA filing path for ampreloxetine in MSA patients with symptomatic nOH. The sale of TRELEGY ELLIPTA royalty interests to Royalty Pharma for over $1.5 billion enables debt elimination and a planned return of capital to shareholders.

Theravance Biopharma reported their Q1 2022 financial results, highlighting their execution against the business plan and remaining on track to become sustainably cash-flow positive by the second half of 2022. YUPELRI's hospital sales performance and market share gains were noted. The company plans to define a path forward for ampreloxetine through discussions with regulators and strategic partners.

Theravance Biopharma reported their Q4 and full year 2021 financial results. YUPELRI saw the highest quarter of net sales since its launch. GSK’s TRELEGY sales reached their highest levels since launch driven by growth in the asthma indication. The company expects to become sustainably cash-flow positive beginning the second half of this year.

Theravance Biopharma reported their Q3 2021 financial results, highlighting their strategic plan execution to become cash-flow positive by the second half of 2022, focusing on YUPELRI growth, R&D streamlining, and portfolio optimization.

Theravance Biopharma reported strong progress in the second quarter of 2021, with increased face-to-face engagements with customers driving continued sales volume and market share growth for YUPELRI.

Theravance Biopharma reported its Q1 2021 financial results, highlighting the continued growth of GSK's TRELEGY and the performance of YUPELRI with partner Viatris, despite pandemic-associated headwinds. The company is focused on advancing its pipeline with four significant clinical readouts expected between now and Q1 2022.

Theravance Biopharma reported its Q4 and full year 2020 financial results, highlighting a critical year of growth for YUPELRI despite the respiratory pandemic. The company is focused on delivering clinical development milestones for ampreloxetine and izencitinib in 2021.

Theravance Biopharma reported total revenue of $18.3 million for Q3 2020. The operating loss was $76.6 million, or $61.1 million excluding share-based compensation expense. The company's implied 35% share of net sales for YUPELRI during Q3 2020 was $13.0 million.

Theravance Biopharma reported revenue of $15.0 million and an operating loss of $72.2 million for the second quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $438.3 million as of June 30, 2020.

Theravance Biopharma reported revenue of $19.9 million and an operating loss of $72.5 million for the first quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $492.1 million as of March 31, 2020. The company is focusing on advancing its pipeline programs, including TD-0903 for COVID-19 related lung injury, and continuing its partnership with Janssen on TD-1473 and TD-5202.

Theravance Biopharma reported fourth-quarter revenue of $29.5 million and full-year revenue of $73.4 million. The company's cash, cash equivalents, and marketable securities totaled $285.8 million as of December 31, 2019.